341 results on '"Kanao, Kent"'
Search Results
52. Prognostic Stratification of the IMDC Intermediate Risk Group After Treatment With First-line Molecular-targeted Therapy for Metastatic Renal Cell Carcinoma
53. A case of castration-resistant prostate cancer with liver metastases achieved a complete response by docetaxel chemotherapy
54. Efficacy of Nivolumab Plus Ipilimumab in a Patient With Renal Cell Carcinoma Concomitant With Cardiac Metastasis: A Case Report
55. Gemcitabine/Cisplatin therapy for an urothelial carcinoma patient undergoing hemodialysis: a case report
56. Predicting the probability of significant prostate cancer in Japanese men with serum prostate-specific antigen less than 10 ng/mL: Development of a novel pre-biopsy nomogram
57. THE IMPACT OF POSITIVE CORE DENSITY ON PREDICTION OF THE PRETREATMENT STAGE OF PROSTATE CANCER: 301
58. Angiogenic, inflammatory and immunologic markers in predicting response to sunitinib in metastatic renal cell carcinoma
59. Preoperative Prognostic Nomogram (Probability Table) for Renal Cell Carcinoma Based on TNM Classification
60. Non-palpable Testicular Embryonal Carcinoma Diagnosed by Ultrasound: A Case Report
61. Clinical and pathologic significance of activation of signal transducer and activator of transcription 3 in prostate cancer
62. Decreased Acetylation of Histone H3 in Renal Cell Carcinoma: A Potential Target of Histone Deacetylase Inhibitors
63. THE THERAPEUTIC EFFECTS OF THE HUMAN INTERLEUKIN-6 RECEPTOR ANTIBODY (TOCILIZUMAB) ON PROSTATE CANCER: 647
64. Preoperative Nomograms for Predicting Stone-Free Rate After Extracorporeal Shock Wave Lithotripsy
65. Three-dimensional ultrasonography in evaluation of benign prostatic hyperplasia
66. A case in which bladder cancer invaded the ureteral orifice and was resected via photodynamic diagnosis‐assisted transurethral resection involving orally administered 5‐aminolevulinic acid
67. Increased infiltration of CCR4‐positive regulatory T cells in prostate cancer tissue is associated with a poor prognosis
68. Prostate-specific antigen response patterns during cabazitaxel therapy in patients with metastatic castration-resistant prostate cancer
69. Optimal Timing of Cabazitaxel Introduction for Japanese Patients With Metastatic Castration-resistant Prostate Cancer
70. Targeting lactate dehydrogenase‑A promotes docetaxel‑induced cytotoxicity predominantly in castration‑resistant prostate cancer cells
71. Sub-classification of patients with intermediate-risk metastatic renal cell carcinoma treated with targeted therapy
72. Impact of inflammatory marker levels one month after the first-line targeted therapy initiation on progression-free survival prediction in patients with metastatic clear cell renal cell carcinoma
73. 膀胱憩室内に発生した神経内分泌癌の1例
74. Impact of Second-Line Targeted Therapy Dose Intensity on Patients With Metastatic Renal Cell Carcinoma
75. Impact of a novel biopsy instrument with a 25-mm side-notch needle on the detection of prostate cancer in transrectal biopsy
76. MP05-07 SHOULD GLEASON SCORE AT THE POSITIVE SURGICAL MARGIN APPEAR ON THE PATHOLOGY REPORT FOR ROBOT-ASSISTED RADICAL PROSTATECTOMY?
77. PD64-09 A LONG TERM COMPARISON OF PERSISTENCE OF DRUG THERAPY IN 1,970 PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA
78. MP55-10 IMPORTANCE OF BACTERIAL STONE CULTURE AT TRANSURETHRAL LITHOTRIPSY: WHICH CASES REQUIRE BACTERIAL STONE CULTURE?
79. Impact of a robotic surgical system on treatment choice for men with clinically organ-confined prostate cancer
80. Surgical site infection surveillance after open gastrectomy and risk factors for surgical site infection
81. P1-120 - Gemcitabine/Cisplatin therapy for an urothelial carcinoma patient undergoing hemodialysis: a case report
82. Abstract 4400: Targeting lactate dehydrogenase-A promotes docetaxel induced cytotoxicity predominantly in castration-resistant prostate cancer cells
83. Abstract 3961: Increased CCR4-positive regulatory T cells in biopsy specimen of poor prognosis prostate cancer
84. Utility of a novel biopsy instrument with long side-notch needle in the selection of patients for active surveillance.
85. Is chemical/surgical castration necessary during docetaxel chemotherapy for castration-resistant prostate cancer?
86. PD26-08 A LONG TERM COMPARISON OF ADHERENCE OF DRUG THERAPY IN 1,917 PATIENTS WITH OVERACTIVE BLADDER
87. MP43-14 UTILITY OF A NOVEL BIOPSY INSTRUMENT WITH LONG SIDE-NOTCH NEEDLE IN THE SELECTION OF PATIENTS FOR ACTIVE SURVEILLANCE
88. MP11-10 CLINICAL PHARMACOKINETICS OF BETA-LACTAM ANTIBIOTICS IN PROSTATE TISSUE, AND DOSING CONSIDERATIONS FOR PROSTATITIS BASED ON SITE-SPECIFIC PHARMACODYNAMICS
89. MP16-07 USEFULNESS OF INFLAMMATORY MARKER DYNAMICS ONE MONTH AFTER THE FIRST-LINE TARGETED THERAPY INITIATION FOR PFS PREDICTION IN PATIENTS WITH METASTATIC CLEAR CELL RENAL CELL CARCINOMA
90. MP67-11 THE IMPACT OF MODIFIED INTERNATIONAL METASTATIC RENAL CELL CARCINOMA DATABASE CONSORTIUM MODEL USING A TWO-STEP STRATIFICATION PROCESS
91. Prognostic value of neutrophil-to-lymphocyte ratio in patients with metastatic renal cell carcinoma treated with first-line and subsequent second-line targeted therapy: A proposal of the modified-IMDC risk model11Dr. Mizuno reports grants from The Japan Agency for Medical Research and Development (AMED), personal fees from Pfizer, grants and personal fees from Novartis, during the conduct of the study. Dr. Mikami reports grants from The Japan Agency for Medical Research and Development (AMED) during the conduct of the study. Dr. Oya reports grants from The Japan Agency for Medical Research and Development (AMED), grants and personal fees from Pfizer, grants and personal fees from Novartis, personal fees from Bayer, during the conduct of the study. No potential conflicts of interest were disclosed by the other authors.
92. Novel algorithm for management of acute epididymitis
93. Impact of inflammatory marker levels one month after the first-line targeted therapy initiation on progression-free survival prediction in patients with metastatic clear cell renal cell carcinoma.
94. Effect of reclassification of the IMDC model in patients with metastatic renal cell carcinoma treated with targeted therapy in the first-line and second-line settings
95. S&T-57 NOVEL TRU-CUT NEEDLE WITH 25 MM CUTTING LENGTH IMPROVES THE DETECTION RATE OF PROSTATE CANCER IN TRANSRECTAL PROSTATE BIOPSY
96. MP18-14 CAN SMALL LESIONS OF GLEASON 3+4 BE LEFT UNTREATED IN FOCAL THERAPY? ANALYSIS OF RADICAL PROSTATECTOMY SPECIMENS.
97. MP27-18 IMPACT OF MAXIMUM TUMOR DIAMETER ADJUSTED BY PRIMARY TUMOR LOCATION IN PATIENTS WITH UPPER TRACT UROTHELIAL CARCINOMA MANAGED BY RADICAL NEPHROURETERECTOMY: THE MULTI-INSTITUTIONAL STUDY
98. Plasma fibrinogen level: an independent prognostic factor for disease-free survival and cancer-specific survival in patients with localised renal cell carcinoma
99. Optimal method for measuring tumor extent in needle biopsy specimens to identify small-volume prostate cancer
100. MP16-18 DEVELOPMENT OF AN ALGORITHM FOR PREDICTING SEVERE ACUTE EPIDIDYMITIS
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.